Takeda CFO makes switch to Walgreens Boots Alliance

8 March 2018

James Kehoe (pictured above), chief financial officer (CFO) of Takeda Pharmaceutical (TYO: 4502), is leaving his role with the Japanese pharma company to become global CFO of Walgreens Boots Alliance (Nasdaq: WBA).

The Irishman has been in the Tokyo-based position since June 2016 but will leave at the end of the month and in June will take up his new job stateside with a company that calls itself the largest pharmacy-led, health and wellbeing enterprise across the USA and Europe.

Mr Kehoe said that he felt there was “no more important company at the junction of health care and retail than Walgreens Boots Alliance”, calling it a “pivotal moment” in its history.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK